NASDAQ:KITE - (KITE) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$179.79
+0.30 (1.20%)
Get New (KITE) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KITE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KITE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (KITE) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $179.79.

N/A

The current consensus among 0 investment analysts is to n/a stock in (KITE). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017WedbushUpgradeUnderperform ➝ NeutralLow
i
Rating by D. Nierengarten at Wedbush
8/29/2017Canaccord GenuityDowngradeBuy ➝ HoldLow
i
Rating by John Newman at Canaccord Genuity
8/28/2017GuggenheimDowngradeBuy ➝ Neutral$128.00Low
i
8/28/2017SunTrust BanksDowngradeBuy ➝ HoldMedium
i
8/28/2017BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
8/10/2017Stifel NicolausReiterated RatingHold$74.00Low
i
8/9/2017Jefferies Financial GroupReiterated RatingBuy$121.00 ➝ $135.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/9/2017Canaccord GenuitySet Price TargetBuy$115.00 ➝ $120.00Medium
i
Rating by John Newman at Canaccord Genuity
7/13/2017Maxim GroupDowngradeBuy ➝ Hold$88.00Low
i
Rating by Jason McCarthy at Maxim Group
7/10/2017Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$101.00 ➝ $121.00Medium
i
Rating by Biren Amin at Jefferies Financial Group Inc.
7/10/2017Canaccord GenuitySet Price TargetBuy$115.00Medium
i
Rating by John Newman at Canaccord Genuity
7/4/2017Roth CapitalReiterated RatingBuy$93.00Medium
i
Rating by Mark Breidenbach at Roth Capital
7/4/2017CowenReiterated RatingOutperformMedium
i
6/27/2017Canaccord GenuitySet Price TargetBuy$115.00N/A
i
Rating by John Newman at Canaccord Genuity
6/26/2017CowenReiterated RatingOutperformMedium
i
6/26/2017Jefferies Financial GroupReiterated RatingBuy$101.00Medium
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/16/2017WedbushReiterated RatingUnderperform$54.00Low
i
Rating by D. Nierengarten at Wedbush
6/9/2017Jefferies Financial GroupReiterated RatingBuy$101.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/8/2017BTIG ResearchUpgradeNeutral ➝ Buy$100.00High
i
6/7/2017CowenReiterated RatingBuyHigh
i
6/6/2017Canaccord GenuitySet Price TargetBuy$90.00High
i
Rating by John Newman at Canaccord Genuity
5/30/2017(FBRC)Reiterated RatingBuyLow
i
Rating by Edward White at (FBRC)
5/19/2017Jefferies Financial GroupSet Price TargetBuy$101.00Medium
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/19/2017HC WainwrightReiterated RatingBuy$85.00Medium
i
Rating by Corey Davis at HC Wainwright
5/19/2017BTIG ResearchReiterated RatingNeutralMedium
i
5/15/2017Raymond JamesDowngradeOutperform ➝ Mkt PerformN/A
i
5/9/2017Maxim GroupSet Price TargetBuy$88.00High
i
Rating by Jason McCarthy at Maxim Group
5/9/2017WedbushDowngradeNeutral ➝ Underperform$60.00 ➝ $54.00High
i
Rating by D. Nierengarten at Wedbush
5/9/2017The Goldman Sachs GroupBoost Price TargetBuy$85.00 ➝ $89.00High
i
5/9/2017CowenReiterated RatingNeutral$74.00High
i
5/9/2017Canaccord GenuityReiterated RatingBuy$90.00High
i
Rating by John Newman at Canaccord Genuity
5/9/2017(FBRC)Reiterated RatingOutperform ➝ Outperform$90.00 ➝ $91.00Medium
i
Rating by Edward White at (FBRC)
5/8/2017Raymond JamesReiterated RatingOutperform ➝ Mkt PerformHigh
i
5/8/2017UBS GroupDowngradeOutperform ➝ Market PerformN/A
i
4/20/2017Canaccord GenuitySet Price TargetBuy$90.00Low
i
Rating by John Newman at Canaccord Genuity
4/20/2017Jefferies Financial GroupReiterated RatingBuyMedium
i
Rating by Biren Amin at Jefferies Financial Group Inc.
4/6/2017Roth CapitalReiterated RatingBuy$93.00High
i
Rating by Mark Breidenbach at Roth Capital
4/6/2017CowenReiterated RatingOutperformHigh
i
4/3/2017Canaccord GenuityReiterated RatingBuy$90.00High
i
Rating by John Newman at Canaccord Genuity
4/3/2017Maxim GroupSet Price TargetBuy$84.00 ➝ $100.00High
i
Rating by Jason McCarthy at Maxim Group
4/3/2017Jefferies Financial GroupReiterated RatingBuy$101.00High
i
Rating by Biren Amin at Jefferies Financial Group Inc.
4/3/2017WedbushReiterated RatingNeutral$60.00High
i
Rating by D. Nierengarten at Wedbush
3/30/2017BTIG ResearchReiterated RatingHoldLow
i
3/20/2017Roth CapitalSet Price TargetBuy$93.00High
i
Rating by Mark Breidenbach at Roth Capital
3/16/2017Jefferies Financial GroupReiterated RatingBuy$82.00 ➝ $101.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
3/15/2017Canaccord GenuityReiterated RatingBuy$75.00 ➝ $90.00Low
i
Rating by John Newman at Canaccord Genuity
3/13/2017Standpoint ResearchDowngradeBuy ➝ Hold$85.00Low
i
3/11/2017Maxim GroupReiterated RatingBuy$84.00N/A
i
Rating by Jason McCarthy at Maxim Group
3/7/2017CowenReiterated RatingOutperformN/A
i
3/6/2017Royal Bank of CanadaBoost Price TargetOutperform$85.00 ➝ $95.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
3/6/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$85.00 ➝ $95.00N/A
i
3/3/2017BTIG ResearchReiterated RatingNeutralN/A
i
3/3/2017WedbushReiterated RatingNeutral$46.00 ➝ $60.00N/A
i
Rating by D. Nierengarten at Wedbush
3/3/2017Stifel NicolausDowngradeBuy ➝ Hold$74.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
3/2/2017CitigroupDowngradeBuy ➝ Neutral$62.00 ➝ $87.00N/A
i
3/1/2017Maxim GroupBoost Price TargetBuy ➝ Buy$77.00 ➝ $84.00N/A
i
Rating by Jason McCarthy at Maxim Group
2/28/2017Roth CapitalSet Price TargetBuy$83.00N/A
i
Rating by Mark Breidenbach at Roth Capital
2/28/2017Canaccord GenuitySet Price TargetBuy$75.00N/A
i
Rating by John Newman at Canaccord Genuity
2/28/2017HC WainwrightSet Price TargetBuy ➝ Buy$78.00 ➝ $85.00N/A
i
Rating by Corey Davis at HC Wainwright
2/28/2017Standpoint ResearchReiterated RatingBuy ➝ Buy$85.00N/A
i
2/27/2017Jefferies Financial GroupReiterated RatingBuy$72.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
2/22/2017HC WainwrightReiterated RatingBuy$78.00 ➝ $85.00N/A
i
Rating by Corey Davis at HC Wainwright
2/22/2017Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market PerformN/A
i
2/1/2017WedbushInitiated CoverageNeutral$46.00N/A
i
Rating by D. Nierengarten at Wedbush
1/24/2017Jefferies Financial GroupReiterated RatingBuy$72.00N/A
i
1/17/2017Maxim GroupReiterated RatingBuy$77.00N/A
i
Rating by Jason McCarthy at Maxim Group
1/8/2017(FBRC)Set Price TargetBuy$78.00N/A
i
Rating by Edward White at (FBRC)
1/4/2017Roth CapitalInitiated CoverageBuy$68.00N/A
i
Rating by M. Breidenbach at Roth Capital
12/12/2016Stifel NicolausReiterated RatingBuyN/A
i
Rating by Thomas Shrader at Stifel Nicolaus
12/9/2016Jefferies Financial GroupReiterated RatingBuy$72.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
12/7/2016HC WainwrightReiterated RatingBuy$78.00N/A
i
Rating by Corey Davis at HC Wainwright
12/6/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
12/5/2016Maxim GroupSet Price TargetBuy$77.00N/A
i
Rating by Jason McCarthy at Maxim Group
12/5/2016Stifel NicolausReiterated RatingBuy$74.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
11/29/2016Canaccord GenuitySet Price TargetBuy$75.00N/A
i
Rating by John Newman at Canaccord Genuity
11/26/2016Stifel NicolausReiterated RatingBuy$74.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
11/24/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Michael Yee at Royal Bank of Canada
11/23/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
11/22/2016BTIG ResearchReiterated RatingHoldN/A
i
11/21/2016HC WainwrightInitiated CoverageBuy$78.00N/A
i
11/13/2016BTIG ResearchReiterated RatingHoldN/A
i
11/10/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
11/1/2016Jefferies Financial GroupReiterated RatingBuy$72.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
10/19/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
10/19/2016Maxim GroupSet Price TargetBuy$77.00N/A
i
Rating by Jason McCarthy at Maxim Group
10/19/2016Canaccord GenuitySet Price TargetBuy$75.00N/A
i
Rating by John Newman at Canaccord Genuity
10/18/2016Jefferies Financial GroupReiterated RatingBuy$72.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
10/10/2016The Goldman Sachs GroupReiterated RatingBuy$70.00N/A
i
10/9/2016BTIG ResearchReiterated RatingNeutralN/A
i
10/7/2016Canaccord GenuityReiterated RatingBuy$75.00N/A
i
Rating by John Newman at Canaccord Genuity
10/6/2016Maxim GroupSet Price TargetBuy$77.00N/A
i
Rating by Jason McCarthy at Maxim Group
10/6/2016Stifel NicolausSet Price TargetBuy$74.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
9/30/2016Stifel NicolausReiterated RatingBuy$74.00N/A
i
Rating by thomas shrader at Stifel Nicolaus
9/27/2016(FBRC)Reiterated RatingOutperform$78.00N/A
i
Rating by Edward White at (FBRC)
9/27/2016BTIG ResearchReiterated RatingNeutralN/A
i
9/27/2016Jefferies Financial GroupReiterated RatingBuy$72.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
9/27/2016BarclaysBoost Price TargetEqual Weight$60.00 ➝ $65.00N/A
i
Rating by jonathan eckard at Barclays PLC
9/22/2016Stifel NicolausReiterated RatingBuy$74.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
9/19/2016Jefferies Financial GroupReiterated RatingBuy$72.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/30/2016BTIG ResearchInitiated CoverageNeutralN/A
i
8/9/2016MizuhoSet Price TargetBuy$80.00N/A
i
Rating by eric criscuolo at Mizuho
8/9/2016BarclaysSet Price TargetHold$58.00 ➝ $60.00N/A
i
8/9/2016Maxim GroupReiterated RatingBuy$87.00 ➝ $77.00N/A
i
Rating by Jason McCarthy at Maxim Group
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
7/26/2016Canaccord GenuityReiterated RatingBuy$75.00N/A
i
Rating by John Newman at Canaccord Genuity
7/22/2016MizuhoReiterated RatingBuy$80.00N/A
i
Rating by Eric Criscuolo at Mizuho
7/15/2016MizuhoReiterated RatingBuy$80.00N/A
i
Rating by Eric Criscuolo at Mizuho
7/13/2016Canaccord GenuityReiterated RatingBuy$75.00N/A
i
Rating by John Newman at Canaccord Genuity
7/13/2016Stifel NicolausBoost Price TargetHold ➝ Buy$63.00 ➝ $74.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
7/10/2016(FBRC)Reiterated RatingOutperform$75.00N/A
i
Rating by Edward White at (FBRC)
7/9/2016Jefferies Financial GroupReiterated RatingBuy$72.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
7/8/2016MizuhoReiterated RatingHold$80.00N/A
i
Rating by Eric Criscuolo at Mizuho
7/6/2016BarclaysInitiated CoverageEqual Weight$58.00N/A
i
6/20/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
(Data available from 6/14/2016 forward)
(KITE) logo
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).
Read More

Today's Range

Now: $179.79
$179.79
$179.79

50 Day Range

MA: N/A

52 Week Range

Now: $179.79
$39.82
$179.99

Volume

N/A

Average Volume

1,652,408 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (KITE)?

The following Wall Street analysts have issued reports on (KITE) in the last year:
View the latest analyst ratings for KITE.

What is the current price target for (KITE)?

0 Wall Street analysts have set twelve-month price targets for (KITE) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (KITE) in the next year.
View the latest price targets for KITE.

What is the current consensus analyst rating for (KITE)?

(KITE) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KITE.

How do I contact (KITE)'s investor relations team?

(KITE)'s physical mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company's listed phone number is +1-310-8249999. The official website for (KITE) is www.kitepharma.com.